Regenerative medicine represents one of the most promising frontiers in modern healthcare, offering transformative solutions to restore damaged tissues and organs through advanced biotechnological approaches. The field integrates stem cell research, biomaterials, tissue engineering, and 3D bioprinting to develop innovative therapies addressing conditions that remain challenging or impossible to treat with conventional medicine.

Despite rapid advancements, the widespread adoption of regenerative medicine faces multiple barriers. These include challenges in manufacturing scalability, regulatory approval pathways, standardisation of bioprinted tissues, and ensuring compliance with Good Manufacturing Practice (GMP) for clinical applications. Additionally, securing sustainable investment and establishing clear reimbursement frameworks for advanced therapies remain critical for their commercial success.

The Regenerative Medicine Helix is an international Open Innovation network dedicated to accelerating the adoption of biofabrication and regenerative technologies. Launched as part of the KeratOPrinter initiative, this Helix serves as a focal point for impact, exploitation, and knowledge-sharing among key stakeholders, including:

• Biomedical researchers developing new therapeutic applications.

• Healthcare professionals integrating regenerative medicine into clinical practice.

• Biotech and MedTech industries advancing 3D bioprinting and stem cell-based therapies.

• Regulatory bodies and policymakers shaping the future of advanced therapies.

• Investors and funding agencies fostering sustainable business models for regenerative medicine